ClinicalTrials.gg
CompletedNCT02036515Updated Sep 13, 2018Results posted

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
8th of 28
464 · median 83
Started
2014
with 3 others
Phase 3
11 of 28
none open now
Registered
13th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin. The primary objective of the trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides greater reduction in A1C compared with the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses of ertugliflozin.

Read the detailed description

The duration of the trial will be approximately 69 weeks. This will include a 1-week Screening Period, an up to 12-week wash-off/titration /dose-stabilization period, a 2-week single-blind, placebo run-in period, a 52-week double-blind, placebo-controlled treatment period (including a 26-week Phase A and 26-week Phase B), and a post-treatment telephone contact 14 days after the last dose of blinded investigational product.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus (T2DM)
  • On stable diabetes therapy of metformin with either sitagliptin or another dipeptidyl peptidase-4 (DPP-4) inhibitor or a sulfonylurea (SU) prior to study participation and is willing to wash-off/switch from another DPP-4 inhibitor/SU to sitagliptin
  • (BMI) greater than or equal to 18.0 kg/m\^2
  • Male, female or surgically sterile female
  • If a female of , agrees to remain abstinent or to use (or have their partner use) 2 acceptable combinations of while participating in the trial and for 14 days after the last use of study drug

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug- or chemical-induced, and post-organ transplant)
  • A known or intolerance to any sodium-glucose co-transporter 2 (SGLT2) or DPP-4 inhibitor
  • On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable
  • Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable
  • Has been treated with insulin (except for short-term use [\<= 7 days]), injectable antihyperglycemic agents (AHAs) (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other sodium-glucose co-transporter 2 (SGLT2) inhibitors, alpha glucosidase inhibitors or meglitinides, bromocriptine (Cycloset™), colesevelam (Welchol™), or any other non-protocol approved AHAs within 12 weeks of study participation
  • Has active, obstructive uropathy or indwelling urinary catheter
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study participation
  • A history of ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
  • Known history of (HIV)
  • Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • A medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or active symptomatic gallbladder disease
  • Has any clinically significant malabsorption condition
  • If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation
  • Has been previously randomized in a study with ertugliflozin
  • Has participated in other studies involving an drug within 30 days prior or during study participation
  • Has undergone a surgical procedure within 6 weeks prior to or planned major surgery during study participation
  • Has a positive urine pregnancy test
  • Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication
  • Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication
  • Excessive consumption of alcoholic beverages or binge drinking
  • Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
464 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin, 5 mg, oral, once daily for 52 weeks

    Drug: Ertugliflozin 5 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin · Drug: Placebo for ertugliflozin 10 mg

  • Experimental
    Ertugliflozin 15 mg

    Ertugliflozin, 15 mg, oral, once daily for 52 weeks

    Drug: Ertugliflozin 15 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin

  • Placebo comparator
    Placebo

    Matching placebo to ertuglifozin, oral, once daily for 52 weeks

    Drug: Placebo for ertugliflozin 5 mg · Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride · Biological: Insulin · Drug: Placebo for ertugliflozin 10 mg

Interventions

  • Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks

    Also known as: MK-8835, PF-04971729

  • Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks

    Also known as: MK-8835, PF-04971729

  • DrugPlacebo for ertugliflozin 5 mg

    Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks

  • Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.

    Also known as: Glucophage, Glucophage XR

  • Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.

    Also known as: JANUVIA®

  • Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion

    Also known as: AMARYL

  • BiologicalInsulin

    Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.

  • DrugPlacebo for ertugliflozin 10 mg

    Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C at Week 26

    A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Experiencing An Adverse Event (AE)

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

    Time frame: Up to Week 54

  3. Percentage of Participants Discontinuing Study Treatment Due to an AE

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

    Time frame: Up to Week 52

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

    The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Body Weight at Week 26

    The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  3. Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26

    A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Week 26

  4. Change From Baseline in Sitting Systolic Blood Pressure at Week 26

    The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  5. Change From Baseline in Hemoglobin A1C at Week 52

    A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  6. Change From Baseline in FPG at Week 52

    The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  7. Change From Baseline in Body Weight at Week 52

    The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  8. Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52

    A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Week 52

  9. Change From Baseline in Sitting Systolic Blood Pressure at Week 52

    The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Sitting Diastolic Blood Pressure at Week 26

    The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  11. Change From Baseline in Sitting Diastolic Blood Pressure at Week 52

    The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  12. Percentage of Participants Receiving Glycemic Rescue Medication by Week 26

    Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).

    Time frame: Week 26

  13. Percentage of Participants Receiving Glycemic Rescue Medication by Week 52

    Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).

    Time frame: Week 52

  14. Time to Initiation of Glycemic Rescue by Week 26

    Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.

    Time frame: Up to Week 26 (plus 30 days for 1 placebo participant)

  15. Time to Initiation of Glycemic Rescue by Week 52

    Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.

    Time frame: Up to week 52

  16. Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value

    HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]

    Time frame: Baseline

  17. Change From Baseline in HOMA-%β at Week 26

    HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  18. Change From Baseline in HOMA-%β at Week 52

    HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

  19. Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score

    The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).

    Time frame: Baseline

  20. Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26

    The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  21. Change From Baseline in EQ-5D-3L Score at Week 52

    The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 52

07

Results

Posted Jul 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Started156155153
Treated156153153
Completed151143139
Not completed51214
Withdrew: Adverse event112
Withdrew: Lost to follow-up020
Withdrew: Non-compliance with study drug002
Withdrew: Screen failure020
Withdrew: Withdrawal by subject479
Withdrew: Hyperglycemia001

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C at Week 26

A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1C at Week 26
PercentErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Hemoglobin A1C at Week 26-0.78 (-0.91 to -0.65)-0.86 (-0.99 to -0.72)-0.09 (-0.23 to -0.04)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares mean: -0.69 · 95% CI -0.87 to -0.50Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares mean: -0.76 · 95% CI -0.95 to -0.58Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
PrimaryPercentage of Participants Experiencing An Adverse Event (AE)

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

Time frame:
Up to Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing An Adverse Event (AE)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Experiencing An Adverse Event (AE)57.760.163.4
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percentage: -5.7 · 95% CI -16.5 to 5.2
  • Ertugliflozin 15 mg vs Placebo · Difference in percentage: -3.3 · 95% CI -14.1 to 7.6
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing Study Treatment Due to an AE
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Discontinuing Study Treatment Due to an AE4.53.93.9
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percentage: 0.6 · 95% CI -4.4 to 5.6
  • Ertugliflozin 15 mg vs Placebo · Difference in percentage: 0.0 · 95% CI -4.9 to 4.9
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 26

The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26-26.91 ± -32.58-33.04 (-38.71 to -27.36)-1.76 (-7.70 to 4.18)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Differenc in least squares means: -25.15 · 95% CI -32.76 to -17.54Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -31.28 · 95% CI -38.90 to -23.66Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
SecondaryChange From Baseline in Body Weight at Week 26

The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 26
kgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 26-3.35 (-3.78 to -2.91)-3.04 (-3.48 to -2.60)-1.32 (-1.77 to -0.87)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -2.03 · 95% CI -2.65 to -1.40Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -1.72 · 95% CI -2.35 to -1.09Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
SecondaryPercentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 2632.139.917.0
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.16 · 95% CI 1.74 to 5.72Logistic regression model fitted with terms for treatment, baseline A1C, baseline eGFR and prior antihyperglycemic medication.
  • Ertugliflozin 15 mg vs Placebo · Regression, Logistic · p = <0.001 · Difference in least squares means: 4.43 · 95% CI 2.44 to 8.02Logistic regression model fitted with terms for treatment, baseline A1C, baseline eGFR and prior antihyperglycemic medication.
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26

The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline130.87 ± 0.62130.87 ± 0.62130.87 ± 0.62
Change from baseline-3.81 ± 0.87-4.82 ± 0.88-0.88 ± 0.93
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = 0.019 · Difference in least squares means: -2.93 · 95% CI -5.36 to -0.49Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = 0.002 · Difference in least squares means: -3.94 · 95% CI -6.39 to -1.50Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication
SecondaryChange From Baseline in Hemoglobin A1C at Week 52

A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1C at Week 52
PercentErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Hemoglobin A1C at Week 52-0.75 (-0.90 to -0.59)-0.81 (-0.97 to -0.66)0.02 (-0.15 to 0.19)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -0.76 · 95% CI -0.98 to -0.54
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -0.83 · 95% CI -1.05 to -0.61
SecondaryChange From Baseline in FPG at Week 52

The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 52
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in FPG at Week 52-25.57 (-30.91 to -20.23)-26.38 (-31.80 to -20.97)3.19 (-3.08 to 9.47)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -28.76 · 95% CI -36.44 to -21.09
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -29.58 · 95% CI -37.30 to -21.85
SecondaryChange From Baseline in Body Weight at Week 52

The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 52
kgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 52-3.46 (-4.07 to -2.85)-2.83 (-3.45 to -2.21)-0.95 (-1.65 to -0.26)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -2.51 · 95% CI -3.43 to -1.59
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -1.88 · 95% CI -2.81 to -0.95
SecondaryPercentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 5233.332.713.7
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Odds ratio (or): 3.63 · 95% CI 1.98 to 6.64
  • Ertugliflozin 15 mg vs Placebo · Odds ratio (or): 4.02 · 95% CI 2.22 to 7.28
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 52

The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 52
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline130.92 ± 0.62130.92 ± 0.62130.92 ± 0.62
Change from baseline-4.16 ± 0.95-4.09 ± 0.960.83 ± 1.14
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -4.99 · 95% CI -7.82 to -2.15
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -4.92 · 95% CI -7.76 to -2.07
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 26

The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline78.42 ± 0.3678.42 ± 0.3678.42 ± 0.36
Change from baseline-1.68 ± 0.61-1.81 ± 0.62-0.43 ± 0.65
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -1.24 · 95% CI -2.97 to 0.48
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -1.38 · 95% CI -3.11 to 0.36
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 52

The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 52
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline78.44 ± 0.3678.44 ± 0.3678.44 ± 0.36
Change from baseline-1.52 ± 0.61-1.38 ± 0.62-0.53 ± 0.73
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -0.99 · 95% CI -2.82 to 0.84
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -0.85 · 95% CI -2.69 to 0.99
SecondaryPercentage of Participants Receiving Glycemic Rescue Medication by Week 26

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving Glycemic Rescue Medication by Week 26
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Receiving Glycemic Rescue Medication by Week 261.32.016.3
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percent: -15.1 · 95% CI -21.9 to -9.4
  • Ertugliflozin 15 mg vs Placebo · Difference in percent: -14.4 · 95% CI -21.3 to -8.5
SecondaryPercentage of Participants Receiving Glycemic Rescue Medication by Week 52

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving Glycemic Rescue Medication by Week 52
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Receiving Glycemic Rescue Medication by Week 5212.813.741.8
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percentage: -29.0 · 95% CI -38.3 to -19.4
  • Ertugliflozin 15 mg vs Placebo · Difference in percentage: -28.1 · 95% CI -37.5 to -18.4
SecondaryTime to Initiation of Glycemic Rescue by Week 26

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.

Time frame:
Up to Week 26 (plus 30 days for 1 placebo participant)
Reported as:
Number · Days
Time to Initiation of Glycemic Rescue by Week 26
DaysErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Minimum time to initiation of glycemic rescue1354326
Maximum time to initiation of glycemic rescue141147212
SecondaryTime to Initiation of Glycemic Rescue by Week 52

Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.

Time frame:
Up to week 52
Reported as:
Number · Days
Time to Initiation of Glycemic Rescue by Week 52
DaysErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Minimum time to initiation of glycemic rescue1354326
Maximum time to initiation of glycemic rescue295299327
SecondaryBaseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]

Time frame:
Baseline
Reported as:
Mean · Percentage
Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value
PercentageErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline Homeostasis Model Assessment of β-cell Function (HOMA-%β) Value47.99 ± 23.89048.54 ± 34.78248.04 ± 30.733
SecondaryChange From Baseline in HOMA-%β at Week 26

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage
Change From Baseline in HOMA-%β at Week 26
PercentageErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in HOMA-%β at Week 2613.28 (8.87 to 17.68)12.43 (7.94 to 16.93)0.52 (-4.08 to 5.12)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: 12.75 · 95% CI 6.83 to 18.68
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: 11.91 · 95% CI 5.94 to 17.88
SecondaryChange From Baseline in HOMA-%β at Week 52

HOMA-%β is a well-accepted means of assessing fasting β-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\]. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percentage
Change From Baseline in HOMA-%β at Week 52
PercentageErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in HOMA-%β at Week 5210.85 (6.29 to 15.41)10.93 (6.24 to 15.61)-1.93 (-6.88 to 3.02)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: 12.78 · 95% CI 6.54 to 19.03
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: 12.86 · 95% CI 6.54 to 19.18
SecondaryBaseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score

The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).

Time frame:
Baseline
Reported as:
Mean · Score on a scale
Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score
Score on a scaleErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score0.88 ± 0.1660.89 ± 0.1820.90 ± 0.144
SecondaryChange From Baseline in EQ-5D-3L Questionnaire Score at Week 26

The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26
Score on a scaleErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in EQ-5D-3L Questionnaire Score at Week 260.00 (-0.02 to 0.03)0.02 (-0.00 to 0.04)0.01 (-0.01 to 0.04)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: -0.01 · 95% CI -0.04 to 0.02
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: 0.01 · 95% CI -0.02 to 0.04
SecondaryChange From Baseline in EQ-5D-3L Score at Week 52

The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Score on a scale
Change From Baseline in EQ-5D-3L Score at Week 52
Score on a scaleErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in EQ-5D-3L Score at Week 520.03 (-0.00 to 0.05)-0.00 (-0.03 to 0.03)0.02 (-0.01 to 0.06)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in least squares means: 0.00 · 95% CI -0.04 to 0.04
  • Ertugliflozin 15 mg vs Placebo · Difference in least squares means: -0.02 · 95% CI -0.07 to 0.02

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg (Phase A+B)—13/156 (8.3%)24/156 (15.4%)
Ertugliflozin 15 mg (Phase A+B)—3/153 (2%)18/153 (11.8%)
Placebo (Phase A+B)—8/153 (5.2%)29/153 (19%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventErtugliflozin 5 mg (Phase A+B)Ertugliflozin 15 mg (Phase A+B)Placebo (Phase A+B)
Acute myocardial infarctionCardiac disorders0/1560/1531/153
Abdominal pain lowerGastrointestinal disorders0/1560/1531/153
Non-cardiac chest painGeneral disorders0/1560/1531/153
CholelithiasisHepatobiliary disorders0/1560/1531/153
Liver disorderHepatobiliary disorders0/1561/1530/153
Bone tuberculosisInfections and infestations0/1560/1531/153
Meningitis tuberculousInfections and infestations0/1560/1531/153
Subcutaneous abscessInfections and infestations0/1560/1531/153
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1560/1531/153
Cerebral haemorrhageNervous system disorders0/1561/1530/153
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mg (Phase A+B)Ertugliflozin 15 mg (Phase A+B)Placebo (Phase A+B)
HypoglycaemiaMetabolism and nutrition disorders7/1565/15311/153
Urinary tract infectionInfections and infestations2/1565/1538/153
NasopharyngitisInfections and infestations8/1566/1535/153
Back painMusculoskeletal and connective tissue disorders8/1563/1536/153

Baseline characteristics

All participants as treated population excludes two participants randomized to Ertugliflozin 15 mg but did not receive any treatment.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean59.2 ± 9.359.7 ± 8.658.3 ± 9.259.1 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Female757153199
Male8182100263
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean8.05 ± 0.868.00 ± 0.838.03 ± 0.938.03 ± 0.88
Fasting plasma glucose
Fasting plasma glucose(mg/dL)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean167.7 ± 37.7171.7 ± 39.1169.6 ± 37.8169.7 ± 38.2
Body weight
Body weight(Kilograms)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean87.6 ± 18.686.6 ± 19.586.4 ± 20.886.9 ± 19.6
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean87.0 ± 17.586.9 ± 15.689.9 ± 17.587.9 ± 16.9
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23. PubMed 28921862 ↗
  • Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27. PubMed 32700393 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗
  • Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7. PubMed 31064361 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jun 2016, 26 months.

Results were first posted in Jul 2017, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 15, 2014
StartActual
Mar 12, 2014
Primary completionActual
Jun 6, 2016
CompletionActual
Jun 6, 2016
Results first posted
Jul 24, 2017
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02036515
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 15, 2014
Start date
Mar 12, 2014
Primary completion
Jun 6, 2016
Completion
Jun 6, 2016
Results posted
Jul 24, 2017
Last update
Sep 13, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion